Press Releases News Year None202020192018201720162015201420132012 IVERIC bio, Inc. Announces Closing of Public Offering and Concurrent Private Placement with $160 Million in Gross Proceeds Jun 22, 2020 | IVERIC bio, Inc. Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants Jun 18, 2020 | IVERIC bio, Inc. Announces Proposed Offering of Common Stock and Pre-Funded Warrants and Concurrent Private Placement Jun 17, 2020 | IVERIC bio Announces Positive Zimura 18 Month Data Supporting the 12 Month Efficacy Findings: Continuous Positive Treatment Effect with Favorable Safety Profile in Geographic Atrophy Secondary to Age-Related Macular Degeneration in a Phase 3 Trial Jun 15, 2020 | IVERIC bio to Announce Zimura® 18 Month Data from the OPH2003 Phase 3 Clinical Trial in Geographic Atrophy Secondary to Age-Related Macular Degeneration and Host Conference Call on Monday, June 15, 2020 Jun 14, 2020 | IVERIC bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Jun 02, 2020 | IVERIC bio to Present at the Jefferies 2020 Healthcare Conference May 27, 2020 | IVERIC bio Reports First Quarter 2020 Operational Highlights and Financial Results May 06, 2020 | IVERIC bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) May 04, 2020 | IVERIC bio to Report First Quarter 2020 Financial Results and Host Conference Call on Wednesday, May 6, 2020 Apr 28, 2020 | Pagination First page « first Previous page ‹ previous Page 1 Current page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »
IVERIC bio, Inc. Announces Closing of Public Offering and Concurrent Private Placement with $160 Million in Gross Proceeds Jun 22, 2020 |
IVERIC bio, Inc. Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants Jun 18, 2020 |
IVERIC bio, Inc. Announces Proposed Offering of Common Stock and Pre-Funded Warrants and Concurrent Private Placement Jun 17, 2020 |
IVERIC bio Announces Positive Zimura 18 Month Data Supporting the 12 Month Efficacy Findings: Continuous Positive Treatment Effect with Favorable Safety Profile in Geographic Atrophy Secondary to Age-Related Macular Degeneration in a Phase 3 Trial Jun 15, 2020 |
IVERIC bio to Announce Zimura® 18 Month Data from the OPH2003 Phase 3 Clinical Trial in Geographic Atrophy Secondary to Age-Related Macular Degeneration and Host Conference Call on Monday, June 15, 2020 Jun 14, 2020 |
IVERIC bio to Report First Quarter 2020 Financial Results and Host Conference Call on Wednesday, May 6, 2020 Apr 28, 2020 |
Press Releases News Year None202020192018201720162015201420132012 IVERIC bio, Inc. Announces Closing of Public Offering and Concurrent Private Placement with $160 Million in Gross Proceeds Jun 22, 2020 | IVERIC bio, Inc. Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants Jun 18, 2020 | IVERIC bio, Inc. Announces Proposed Offering of Common Stock and Pre-Funded Warrants and Concurrent Private Placement Jun 17, 2020 | IVERIC bio Announces Positive Zimura 18 Month Data Supporting the 12 Month Efficacy Findings: Continuous Positive Treatment Effect with Favorable Safety Profile in Geographic Atrophy Secondary to Age-Related Macular Degeneration in a Phase 3 Trial Jun 15, 2020 | IVERIC bio to Announce Zimura® 18 Month Data from the OPH2003 Phase 3 Clinical Trial in Geographic Atrophy Secondary to Age-Related Macular Degeneration and Host Conference Call on Monday, June 15, 2020 Jun 14, 2020 | IVERIC bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Jun 02, 2020 | IVERIC bio to Present at the Jefferies 2020 Healthcare Conference May 27, 2020 | IVERIC bio Reports First Quarter 2020 Operational Highlights and Financial Results May 06, 2020 | IVERIC bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) May 04, 2020 | IVERIC bio to Report First Quarter 2020 Financial Results and Host Conference Call on Wednesday, May 6, 2020 Apr 28, 2020 | Pagination First page « first Previous page ‹ previous Page 1 Current page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »
IVERIC bio, Inc. Announces Closing of Public Offering and Concurrent Private Placement with $160 Million in Gross Proceeds Jun 22, 2020 |
IVERIC bio, Inc. Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants Jun 18, 2020 |
IVERIC bio, Inc. Announces Proposed Offering of Common Stock and Pre-Funded Warrants and Concurrent Private Placement Jun 17, 2020 |
IVERIC bio Announces Positive Zimura 18 Month Data Supporting the 12 Month Efficacy Findings: Continuous Positive Treatment Effect with Favorable Safety Profile in Geographic Atrophy Secondary to Age-Related Macular Degeneration in a Phase 3 Trial Jun 15, 2020 |
IVERIC bio to Announce Zimura® 18 Month Data from the OPH2003 Phase 3 Clinical Trial in Geographic Atrophy Secondary to Age-Related Macular Degeneration and Host Conference Call on Monday, June 15, 2020 Jun 14, 2020 |
IVERIC bio to Report First Quarter 2020 Financial Results and Host Conference Call on Wednesday, May 6, 2020 Apr 28, 2020 |
